These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 15626585)

  • 41. Canine versus in vitro data for predicting input profiles of L-sulpiride after oral administration.
    Fotaki N; Symillides M; Reppas C
    Eur J Pharm Sci; 2005 Nov; 26(3-4):324-33. PubMed ID: 16139490
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Anti-anginal and anti-ischemic efficacy of conventional and slow release formulations of isosorbide-5-mononitrate in angina pectoris.
    Thadani U
    Z Kardiol; 1985; 74 Suppl 4():21-4. PubMed ID: 4096067
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Determination of isosorbide dinitrate and its degradation products in pharmaceuticals by gradient RP-HPLC].
    Liu WY
    Yao Xue Xue Bao; 1989; 24(10):797-800. PubMed ID: 2618674
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Investigation of the gastrointestinal transit and in vivo drug release of isosorbide-5-nitrate pellets.
    Fischer W; Boertz A; Davis SS; Khosla R; Cawello W; Sandrock K; Cordes G
    Pharm Res; 1987 Dec; 4(6):480-5. PubMed ID: 3508560
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Randomized crossover trial of isosorbide mononitrate (Elantan 20) and slow-release glyceryl trinitrate in the treatment of angina pectoris.
    Brodie NH; O'Hara H; O'Hara J; Valle-Jones JC
    Pharmatherapeutica; 1985; 4(6):367-75. PubMed ID: 3936056
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Extended-release isosorbide mononitrate for angina.
    Med Lett Drugs Ther; 1994 Feb; 36(915):13-4. PubMed ID: 8283957
    [No Abstract]   [Full Text] [Related]  

  • 47. Long-term effectiveness of extended-release nitrate for the treatment of systolic hypertension.
    Stokes GS; Bune AJ; Huon N; Barin ES
    Hypertension; 2005 Mar; 45(3):380-4. PubMed ID: 15699445
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Bioavailability of isosorbide-5-mononitrate from delayed-action formulations].
    Taylor T; Major RM; Leaf FC; Cook SC; Chasseaud LF; Darragh A; Lambe RF
    Arzneimittelforschung; 1984; 34(11):1584-7. PubMed ID: 6543135
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Serum profile of isosorbide mononitrate after vaginal administration in the third trimester.
    Bates CD; Nicoll AE; Mullen AB; Mackenzie F; Thomson AJ; Norman JE
    BJOG; 2003 Jan; 110(1):64-7. PubMed ID: 12504938
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Anti-ischemic and anti-anginal effects of controlled-release and conventional isosorbide-5-mononitrate in stable angina pectoris.
    Chen YH; Ding PY; Wang SP
    Zhonghua Yi Xue Za Zhi (Taipei); 1998 Oct; 61(10):577-83. PubMed ID: 9830234
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Intracoronary isosorbide mononitrate versus placebo. A double-blind study with quantitative coronary angiography].
    Vieira Botelho R; Feres F; São Thiago LE; Abud R; Carneiro JK; Pinto I; Rego Sousa AG; Rego Sousa JE
    Arq Bras Cardiol; 1995 Oct; 65(4):313-5. PubMed ID: 8728803
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Bioavailability of isosorbide dinitrate and isosorbide-5-mononitrate under steady-state conditions].
    Rietbrock N; Knoll J; Merz PG; Menke G
    Dtsch Med Wochenschr; 1985 Nov; 110(47):1821-5. PubMed ID: 3905327
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Pharmacokinetic profile and bioavailability of a new pharmaceutical formulation of isosorbide-5-mononitrate sustained-release formulation].
    Skutta T; Böttcher B; Brandt L
    Arzneimittelforschung; 1989 Apr; 39(4):507-11. PubMed ID: 2751738
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Pharmacokinetics of low-dose isosorbide dinitrate and metabolites after buccal or oral administration].
    Keller-Stanislawski B; Marschner JP; Rietbrock N
    Arzneimittelforschung; 1992 Jan; 42(1):17-20. PubMed ID: 1586374
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Study of the bioequivalence of a new isosorbide dinitrate tablet formulation compared with the standard preparation].
    Metzner JE; Buchberger D; Häring N; Läuter J
    Arzneimittelforschung; 1997 Jun; 47(6):719-26. PubMed ID: 9281301
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparison of simulated cumulative drug versus time data sets with indices.
    Vertzoni M; Symillides M; Iliadis A; Nicolaides E; Reppas C
    Eur J Pharm Biopharm; 2003 Nov; 56(3):421-8. PubMed ID: 14602186
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Performance Evaluation of Montelukast Pediatric Formulations: Part I-Age-Related In Vitro Conditions.
    Guimarães M; Somville P; Vertzoni M; Fotaki N
    AAPS J; 2022 Jan; 24(1):26. PubMed ID: 35013835
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Colonic Delivery of α-Linolenic Acid by an Advanced Nutrient Delivery System Prolongs Glucagon-Like Peptide-1 Secretion and Inhibits Food Intake in Mice.
    Kamakura R; Raza GS; Mäkilä E; Riikonen J; Kovalainen M; Ueta Y; Lehto VP; Salonen J; Herzig KH
    Mol Nutr Food Res; 2022 Feb; 66(4):e2100978. PubMed ID: 34882959
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Development of a Two-Compartment System In vitro Dissolution Test and Correlation with In vivo Pharmacokinetic Studies for Celecoxib.
    Jiang S; Zhang G; Wang L; Zeng Y; Liu W; Cheng Z
    AAPS PharmSciTech; 2020 Jan; 21(2):59. PubMed ID: 31912248
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Evolution of Choice of Solubility and Dissolution Media After Two Decades of Biopharmaceutical Classification System.
    Bou-Chacra N; Melo KJC; Morales IAC; Stippler ES; Kesisoglou F; Yazdanian M; Löbenberg R
    AAPS J; 2017 Jul; 19(4):989-1001. PubMed ID: 28516359
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.